Johnson & Johnson’s Innovative Medicine franchise is projected to drive growth in the fourth quarter despite increasing competition and legislative headwinds. Key oncology products such as Darzalex and Imbruvica are expected to offset pressure on Stelara sales, which have declined by an estimated low-single-digit percentage year-over-year due to biosimilar entrants. Meanwhile, immunology agents Tremfya and Skyrizi saw combined global sales growth of approximately 18% in the third quarter, fueled by expanded indications and stronger patient uptake in Europe and North America. Analysts highlight that the segment’s mid-single-digit operating margin expansion this year provides financial flexibility to invest in late-stage pipeline candidates, including bispecific antibodies targeting solid tumors slated for filing in 2026.

In the JASMINE trial involving 228 patients with moderate-to-severe systemic lupus erythematosus, nipocalimab achieved a statistically significant improvement in the SLE Responder Index at Week 24 compared with placebo, with a responder rate approximately 35% higher than control. Key secondary endpoints—reduction in corticosteroid use and improvement in joint counts—also reached significance. The safety profile was consistent with prior FcRn blockers, reporting headache and infusion-related reactions in under 10% of subjects and no treatment-related serious adverse events. Johnson & Johnson plans to initiate two pivotal Phase III trials in mid-2026, targeting enrollment of 600 patients each, to support a biologics license application by late 2028.

Johnson & Johnson MedTech has filed a De Novo request with the U.S. Food and Drug Administration for its OTTAVA soft-tissue robotic surgical system, leveraging data from a 50-patient Investigational Device Exemption study. Primary endpoints in general and upper abdominal procedures—such as gastric bypass and hiatal hernia repair—demonstrated a conversion rate to open surgery below 2%, comparable to established platforms, and an overall procedural time reduction of 12% on average. The system’s unified arm architecture and proprietary instrumentation are designed to integrate with the Polyphonic digital ecosystem, aiming to streamline surgical workflows. A second IDE trial in inguinal hernia repair was approved in late 2025, with initial enrollment set at 100 patients across five U.S. centers.